Market Highlights
Global Crohn’s Disease Market has been evaluated as growing market and expected that the market will reach high growth figures in the coming future. Crohn's disease is a type of inflammatory bowel disease (IBD), caused by a combination of environmental, immune and bacterial factors in genetically prone individuals. There are no medications, drugs or surgical procedures that can cure or prevent Crohn's disease. It is expected that the disease affects about 3.2 per 1,000 people in Europe and North America. It is less common in Asia and Africa. Rates have, however, been growing, particularly in the developing world, since last few years.

The Crohn’s Colitis Foundation of America (CCFA) stated, that over 1 Million Americans were diagnosed with Crohn's ulcerative colitis disorders and diseases, with maximum of them aged above 30. Increasing occurrence of Crohn's disease treatment market has triggered a vigorous demand for its therapeutics. A survey conducted by the US Center for Disease Control (CDC) has discovered that the incidence rate of Crohn's disease in the country is 3.1 to 14.6 new cases per 100,000 population annually.

The disease is highly predominant in developed countries, especially in individuals who smoke and consume alcohol.
Major factors leading to the growth of the market includes higher preference for symptomatic therapeutic, better treatment of inflammatory bowel diseases, arrival of enhanced drugs and healthier investments in RD programs. High cost of treatment and lack of early diagnosis techniques are the major factor restricting the market growth.

North America is expected to account for the largest share of the global Crohn’s disease treatment Market size in 2016, followed by Europe, the region will continue to lead the pack during the forecast period. The emerging markets of China and India will also play a key role in driving growth in the long term, primarily due to the anticipated strong uptake of Remicade over the forecast period.

Market Segmentation:
Global Crohn’s Disease Market is segmented on the basis of procedures and drug type. Based on procedures, the market is segmented into Colonoscopy, flexible Sigmoidoscopy, Computerized Tomography (CT), Magnetic Resonance Imaging (MRI), Capsule Endoscopy, Double-Balloon Endoscopy, Small Bowel Imaging. Colonoscopy due to high efficiency and accuracy is expected to command the largest market share during the forecasted period. Further on the basis of drug type the market is classified into antibiotics, anti-diarrheal, immune system suppressors, pain relievers, and anti-inflammatory drugs. Antibiotics are expected to command the largest market share while anti-inflammatory drugs are expected to grow at the highest CAGR during the forecasted period.

Crohn’s Disease Market Players

• Johnson Johnson Services Inc
• Pfizer Inc
• Allergan
• AbbVie Inc
• Bayer AG
• Amgen, Inc
• Takeda Pharmaceutical Company Limited
• UCB S.A
• Ferring B.V
• Eli Lilly and Company
• Hoffman-La Roche
• Bristol-Myers Squibb

among others are some key companies in the global Crohn’s Disease that are listed by MRFR for market research.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: [email protected]